Is clinical effect of autologous conditioned serum in spontaneously occurring equine articular lameness related to ACS cytokine profile?
Open Access
- 8 June 2020
- journal article
- research article
- Published by Springer Nature in BMC Veterinary Research
- Vol. 16 (1) , 1-9
Abstract
Background: Biologic’ therapies, such as autologous conditioned serum (ACS), are gaining popularity in treating orthopaedic conditions in equine veterinary medicine. Evidence is scarce regarding ACS constituents, and large inter-individual differences in cytokine and growth factor content have been demonstrated. The objective of the current study was to investigate the potential association between cytokine and growth factor content of ACS and clinical effect in harness racehorses with spontaneously occurring low-grade articular lameness. Horses received 3 intra-articular injections of ACS administered at approximately 2-week intervals. Lameness evaluation consisting of a trot-up with subsequent flexions tests was performed at inclusion and approximately 2 weeks after the last treatment (re-evaluation); horses were classified as responders when there was no detectable lameness on trot-up and a minimum of 50% reduction in flexion test scores at re-evaluation. Association between clinical outcome (responders vs. non-responders) and age, lameness grades at inclusion (both initial trot-up and after flexion tests), treatment interval, follow-up time and the ACS content of IL-1Ra, IGF-1 and TGF-β was determined by regression modelling.Results: Outcome analysis was available for 19 of 20 included horses; 11 responded to treatment whereas 8 did not. There was considerable inter-individual variability in cytokine/growth factor content of ACS, and in the majority of the horses, the level of IL-10, IL-1β and TNF-α was below the detection limit. In the final multivariate logistic regression model, ACS content of IGF-1 and IL-1Ra was significantly associated with clinical response (P = 0.01 andP = 0.03, respectively). No association with clinical response was found for the other tested variables.Conclusions: The therapeutic benefit of ACS may be related to higher levels of IL-1Ra and IGF-1. Our study corroborates previous findings of considerable inter-individual variability of cytokine- and growth factor content in ACS.Keywords
Funding Information
- Swedish/ Norwegian Foundation for Equine Research (H1247030)
- Norges Forskningsråd (589610)
This publication has 29 references indexed in Scilit:
- Response to: cytokine profile of autologous conditioned serum for treatment of osteoarthritis, in vitro effects on cartilage metabolism and intra-articular levels after injection - authors' replyArthritis Research & Therapy, 2010
- Cytokine profile of autologous conditioned serum for treatment of osteoarthritis, in vitroeffects on cartilage metabolism and intra-articular levels after injectionArthritis Research & Therapy, 2010
- Autologous conditioned serum (Orthokine) is an effective treatment for knee osteoarthritisOsteoarthritis and Cartilage, 2009
- IL-1ra/IGF-1 Gene Therapy Modulates Repair of Microfractured Chondral DefectsClinical Orthopaedics and Related Research, 2007
- Gene-mediated restoration of cartilage matrix by combination insulin-like growth factor-I/interleukin-1 receptor antagonist therapyGene Therapy, 2004
- Phenotypic expression of equine articular chondrocytes grown in three-dimensional cultures supplemented with supraphysiologic concentrations of insulin-like growth factor-IAmerican Journal of Veterinary Research, 2002
- Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist geneGene Therapy, 2002
- IL-1β Induces the Degradation of Equine Articular Cartilage by a Mechanism That Is Not Mediated by Nitric OxideBiochemical and Biophysical Research Communications, 1997
- Cytokine production by normal human monocytes: inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphismClinical and Experimental Immunology, 1995
- Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist.Journal of Clinical Investigation, 1990